Author Details

Ryder, Robert EJ, City Hospital, Birmingham, UK

  • Vol 15, No 2 (2015) - Editorials
    Rehabilitation of pioglitazone
    Details  HTML  PDF
  • Vol 15, No 4 (2015) - Editorials
    Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: the optimal combination may be metformin, pioglitazone and empagliflozin
    Details  HTML  PDF
  • Vol 16, No 2 (2016) - Meeting Reports
    This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
    Details  HTML  PDF
  • Vol 16, No 3 (2016) - Editorials
    Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?
    Details  HTML  PDF
  • Vol 17, No 3 (2017) - Editorials
    What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?
    Details  HTML  PDF